Good Q2 overshadowed by questions on growth; reassuring call commentary
22/07/25 -"Sartorius reported a 5.7% revenue growth in Q2 2025, primarily driven by a 7.8% increase in Bioprocess Solutions, which offset a 2.6% decline in Lab Products & Services. Underlying EBITDA rose by ..."
Pages
67
Language
English
Published on
22/07/25
You may also be interested by these reports :
22/07/25
Sartorius reported a 5.7% revenue growth in Q2 2025, primarily driven by a 7.8% increase in Bioprocess Solutions, which offset a 2.6% decline in Lab ...
22/07/25
Since our analysis of family-owned in-vitro diagnostics specialist BioMerieux’s (Add; France) investment case in July 2023, there has been a notable ...
21/07/25
Getinge’s Q2 2025 profit exceeded estimates. Organic sales increased by 4.1%, and order intake rose by 4.4%, despite nominal declines due to currency ...
17/07/25
The reported FY2024-25 numbers fell short of our expectations due to higher-than-anticipated operating and other financial expenses. In the near ...